R&D channel feed

Verve won tri­al suc­cess with a gene-edit­ing mile­stone. Why don't in­vestors like it?

Last year
Cell/Gene Tx

As­traZeneca's con­cur­rent Imfinzi-chemo-ra­di­a­tion com­bo in lung can­cer miss­es pri­ma­ry end­point in PhI­II tri­al

Last year
Pharma

The­seus Phar­ma­ceu­ti­cals lays off most work­ers and seeks 's­trate­gic al­ter­na­tives' af­ter can­cer pipeline fail­ure

Last year
People

Ipsen, Gen­fit un­veil ad­di­tion­al PhI­II da­ta for rare liv­er dis­ease drug, fur­ther boost­ing reg­u­la­to­ry am­bi­tion

Last year

Bridge­Bio eyes US fil­ing for AT­TR-CM drug af­ter new PhI­II da­ta show ‘fastest’ clin­i­cal ben­e­fit to date

Last year

An­thos' blood thin­ner cuts the risk of bleed­ing amid race to de­vel­op safer an­ti­co­ag­u­lants

Last year

Aclaris los­es 85% of share val­ue af­ter an­oth­er PhII set­back in in­flam­ma­to­ry con­di­tion

Last year

Al­ny­lam’s longer-term RNAi treat­ment low­ers blood pres­sure in mid-stage study

Last year

First da­ta for Lil­ly's RNA treat­ment for heart dis­ease point to long-term dura­bil­i­ty in tiny group of pa­tients

Last year

Verve shares first base edit­ing re­sults in hu­mans, sug­gest­ing ther­a­py can low­er cho­les­terol in pa­tients with ge­net­ic con­di­tion

Last year

Af­ter show­ing We­govy cut car­dio­vas­cu­lar risk by 20%, re­sults de­tail im­pact on death and heart fail­ure

Last year
Pharma

Madri­gal’s got more pos­i­tive da­ta for resme­tirom, plus news from Ali­gos and North­Sea

Last year

Neu­ro­crine ax­es Take­da-part­nered de­pres­sion pro­gram, switch­es fo­cus for seizure drug af­ter PhII fail­ures

Last year

Val­ne­va re­ceives first chikun­gun­ya vac­cine ap­proval af­ter two month de­lay to FDA re­view

Last year
FDA+

No­var­tis plans BTK in­hibitor fil­ing in chron­ic spon­ta­neous ur­ticaria as Celldex’s mid-stage da­ta ex­cite in­vestors

Last year

Re­cur­sion and Bay­er to wind down fi­bro­sis R&D pact af­ter three years, re­fo­cus­ing on can­cer

Last year
Deals

Atara Bio­ther­a­peu­tic­s' stock drops near­ly 50% af­ter PhII tri­al fail in MS

Last year
Cell/Gene Tx

Ful­ly syn­thet­ic genome nears com­ple­tion in a step to­ward un­rav­el­ing ge­net­ic mys­ter­ies

Last year
Discovery
In Focus

As­traZeneca spot­lights bis­pecifics in can­cer as it rais­es guid­ance, while prun­ing rare dis­ease pipeline

Last year
Pharma

As­traZeneca puts down $185M up­front for PhI oral GLP-1 as it shoots for next-gen win

Last year
Deals

Lyell lays off 25% of staff and CMO leaves as com­pa­ny fore­shad­ows first clin­i­cal da­ta next year

Last year
People

BioN­Tech’s ‘ex­ten­sive’ can­cer pipeline comes in­to fo­cus, with em­pha­sis on AD­Cs

Last year
Deals

Gilead re­ports 'flat' Q3 rev­enues, cuts PhI­II Covid tri­al

Last year
Pharma

Bay­er un­veils big changes to busi­ness and head­count to ad­dress ‘not ac­cept­able’ per­for­mance

Last year
Pharma
First page Previous page 61626364656667 Next page Last page
A service from the Financial Times